Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ObsEva closes CHF60mm Series B round

Executive Summary

Women's health firm ObsEva SA raised CHF60mm ($58.9mm) through its Series B round. New buyers HBM Healthcare Investments, New Enterprise Associates (also joins the company's board), OrbiMed, and Rock Springs Capital invested alongside returning backers Sofinnova Ventures, Sofinnova Partners, Novo Ventures, and MS Ventures. Proceeds will fund pipeline development; just prior to the Series B, ObsEva announced that it licensed exclusive global rights (outside of Asia) to Kissei's oral GnRH antagonist KLH2109, which is in Phase II trials for endometriosis.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies